Advanced

Novel approaches to epilepsy treatment.

Sørensen, Andreas T and Kokaia, Merab LU (2012) In Epilepsia
Abstract
The aim of epilepsy treatment is to achieve complete seizure freedom. Nonetheless, numerous side effects and seizure resistance to antiepileptic drugs (AEDs) affecting about 30-40% of all patients are main unmet needs in today's epileptology. For this reason, novel approaches to treat epilepsy are highly needed. Herein, we highlight recent progress in stem-cell-based and gene transfer-based therapies in epilepsy according to findings in animal models and address their potential clinical application. Multiple therapeutic targets are described, including neuropeptides, neurotrophic factors, and inhibitory neurotransmitters. We also address new molecular-genetic approaches utilizing optogenetic technology. The therapeutic strategies presented... (More)
The aim of epilepsy treatment is to achieve complete seizure freedom. Nonetheless, numerous side effects and seizure resistance to antiepileptic drugs (AEDs) affecting about 30-40% of all patients are main unmet needs in today's epileptology. For this reason, novel approaches to treat epilepsy are highly needed. Herein, we highlight recent progress in stem-cell-based and gene transfer-based therapies in epilepsy according to findings in animal models and address their potential clinical application. Multiple therapeutic targets are described, including neuropeptides, neurotrophic factors, and inhibitory neurotransmitters. We also address new molecular-genetic approaches utilizing optogenetic technology. The therapeutic strategies presented herein are predominately aimed toward treatment of partial/focal epilepsies, but could also be envisaged for targeting key seizure propagation areas in the brain. These novel strategies provide proof-of-principle for developing effective treatments for refractory epilepsy in the foreseeable future. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Epilepsia
publisher
Wiley-Blackwell
external identifiers
  • wos:000313116500002
  • pmid:23106744
  • scopus:84872067224
ISSN
0013-9580
DOI
10.1111/epi.12000
language
English
LU publication?
yes
id
73a6d024-4b9f-413c-81a5-2b0560eb8f1e (old id 3160286)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23106744?dopt=Abstract
date added to LUP
2012-11-01 11:54:15
date last changed
2017-10-22 04:51:40
@article{73a6d024-4b9f-413c-81a5-2b0560eb8f1e,
  abstract     = {The aim of epilepsy treatment is to achieve complete seizure freedom. Nonetheless, numerous side effects and seizure resistance to antiepileptic drugs (AEDs) affecting about 30-40% of all patients are main unmet needs in today's epileptology. For this reason, novel approaches to treat epilepsy are highly needed. Herein, we highlight recent progress in stem-cell-based and gene transfer-based therapies in epilepsy according to findings in animal models and address their potential clinical application. Multiple therapeutic targets are described, including neuropeptides, neurotrophic factors, and inhibitory neurotransmitters. We also address new molecular-genetic approaches utilizing optogenetic technology. The therapeutic strategies presented herein are predominately aimed toward treatment of partial/focal epilepsies, but could also be envisaged for targeting key seizure propagation areas in the brain. These novel strategies provide proof-of-principle for developing effective treatments for refractory epilepsy in the foreseeable future.},
  author       = {Sørensen, Andreas T and Kokaia, Merab},
  issn         = {0013-9580},
  language     = {eng},
  publisher    = {Wiley-Blackwell},
  series       = {Epilepsia},
  title        = {Novel approaches to epilepsy treatment.},
  url          = {http://dx.doi.org/10.1111/epi.12000},
  year         = {2012},
}